T2 Biosystems, Inc. Form 3 February 22, 2016

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104 January 31,

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Expires: 2005
Estimated average

burden hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement T2 Biosystems, Inc. [TTOO] Dhanda Rahul (Month/Day/Year) 02/11/2016 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 101 HARTWELL AVENUE (Check all applicable) (Street) 6. Individual or Joint/Group

LEXINGTON, MAÂ 02421

Director _____ 10% Owner _____ Officer Other

(give title below) (specify below)

SVP of Corporate Development

Filing(Check Applicable Line)
_X_Form filed by One Reporting
Person

Form filed by More than One

Table I - Non-Derivative Securities Beneficially Owned

(City) (State)

1.Title of Security 2. Amount of Securities (Instr. 4) Beneficially Owned

(Zip)

Beneficially Owned O
(Instr. 4) Fo

4. Nature of Indirect Beneficial
 Ownership
 Form: (Instr. 5)
 Direct (D)

or Indirect
(I)
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	Ownership Benefici	6. Nature of Indirect Beneficial Ownership
	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)

Edgar Filing: T2 Biosystems, Inc. - Form 3

Stock Option	02/20/2012	02/20/2018	Common Stock	3,000	\$ 0.48	D	Â
Stock Option	02/27/2013	02/27/2019	Common Stock	4,647	\$ 1.16	D	Â
Stock Option	02/05/2014	02/05/2020	Common Stock	2,941	\$ 1.31	D	Â
Stock Option	04/15/2015	04/15/2021	Common Stock	16,470	\$ 1.96	D	Â
Stock Option	01/17/2016	01/17/2022	Common Stock	35,294	\$ 2.45	D	Â
Stock Option	(1)	01/22/2024	Common Stock	13,282	\$ 3.22	D	Â
Stock Option	(2)	07/02/2024	Common Stock	16,600	\$ 10.7	D	Â
Stock Option	(3)	02/13/2025	Common Stock	12,350	\$ 19.95	D	Â
Stock Option	(4)	02/09/2026	Common Stock	35,000	\$ 7.56	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships					
Transfer of the same	Director	10% Owner	Officer	Other		
Dhanda Rahul 101 HARTWELL AVENUE LEXINGTON, MA 02421	Â	Â	SVP of Corporate Development	Â		

Signatures

/s/ Rahul
Dhanda.

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This Stock Option was granted on January 22, 2014 and vesting commenced on the grant date. Options to purchase the underlying shares vest in 48 equal monthly installments beginning on the grant date.
- (2) This Stock Option was granted on July 2, 2014 and vesting commenced on the grant date. Options to purchase the underlying shares vest in 48 equal monthly installments beginning on the grant date.
- (3) This Stock Option was granted on February 13, 2015 and vesting commenced on the grant date. Options to purchase the underlying shares vest in 48 equal monthly installments beginning on the grant date.
- (4) This Stock Option was granted on February 9, 2016 and vesting commenced on the grant date. Options to purchase the underlying shares vest in 48 equal monthly installments beginning on the grant date.

Reporting Owners 2

Edgar Filing: T2 Biosystems, Inc. - Form 3

Â

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.